Drugs / MVR-C5252
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06126744 | Jun 2024 → Dec 2027 expected | malignant glioma | Duke University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVR-C5252 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06126744 ↗ |
| Route | Other | “MVR-C5252, administered intratumorally by convection-enhanced delivery (CED)” NCT06126744 ↗ |